Chapter 5 Systemic therapy for advanced NSCLC, efficacy, and toxicity -- OOL Systemic Treatments for Non-Small-Cell Lung Cancer

Previous | Next

Chapter 5 Systemic therapy for advanced NSCLC, efficacy, and toxicity

Taylor M. Ortiz and Pasi A. Jänne

• Palliate symptoms first.

• Chemotherapy improves survival over best supportive care.

• Some oligometastatic NSCLC is appropriate for aggressive treatment with curative intent.

• Personalized therapy based on EGFR mutation status can improve progression free survival and avoid ineffective therapies.

• Tailoring biologic and chemotherapies based on tumor histology can maximize treatment efficacy.

DOI: 10.1093/med/9780199580484.003.0005

Contents
- Front matter
  - Abbreviations
  - Contributors
- Chapter 1 Molecular biology of lung cancer for the clinician
  - Chapter 1 Molecular biology of lung cancer for the clinician
    - Adi F. Gazdar, Jill E. Larsen, and John D. Minna [Abstract]
- Chapter 2 Staging of lung cancer
  - Chapter 2 Staging of lung cancer
    - Sofie De Craene, Kurt G. Tournoy, and Jan P. van Meerbeeck [Abstract] [Browse Figures]
- Chapter 3 Systemic therapy for early-stage NSCLC
  - Chapter 3 Systemic therapy for early-stage NSCLC
    - Benjamin Besse and Jean-Charles Soria [Abstract]
- Chapter 4 Combined modality therapy for locally advanced NSCLC
  - Chapter 4 Combined modality therapy for locally advanced NSCLC
    - Margaret Edwards and Hak Choy [Abstract]
- Chapter 5 Systemic therapy for advanced NSCLC, efficacy, and toxicity
  - Chapter 5 Systemic therapy for advanced NSCLC, efficacy, and toxicity
    - Taylor M. Ortiz and Pasi A. Jänne [Abstract] [Browse Figures]
    - Key points 5.1 Introduction 5.2 Palliate symptoms first 5.3 Chemotherapy versus best supportive care 5.4 Personalizing care of patients with advanced NSCLC 5.5 The exception for oligometastatic NSCLC 5.6 Personalizing treatments for advanced NSCLC 5.7 Poor performance status Further reading
- Chapter 6 Systemic therapy for recurrent NSCLC, efficacy, and toxicity
  - Chapter 6 Systemic therapy for recurrent NSCLC, efficacy, and toxicity
    - Paul Wheatley-Price and Frances A. Shepherd [Abstract]
- Chapter 7 Palliative care in NSCLC
  - Chapter 7 Palliative care in NSCLC
    - Paul Baas and Wilma Uyterlinde [Abstract] [Browse Figures]
- Chapter 8 Development of new therapeutic agents for treatment of NSCLC
  - Chapter 8 Development of new therapeutic agents for treatment of NSCLC
    - Arun Rajan and Giuseppe Giaccone [Abstract]
- Index
  - Index

This resource summarises the latest evidence-based and practical information on the use of systemic therapies in the management of non-small cell lung cancer (NSCLC) for early stage, locally advanced, and metastatic disease.

Disclaimer: Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work.

Oxford Journals: latest research

Oxford Journals: related titles

Related OUP products

Guest Access | Sign In

Chapter 5 Systemic therapy for advanced NSCLC, efficacy, and toxicity